Journal
LUNG CANCER
Volume 76, Issue 3, Pages 393-396Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2011.11.014
Keywords
Mesothelioma; Clinical trial phase II; Vatalanib; VEGF Receptor; PDGFB; Molecular targeted therapy
Categories
Funding
- National Cancer Institute [CA31946, CA33601]
- [CA45418]
- [CA32291]
- [CA47577]
- [CA77597]
- [CA45389]
- [CA35421]
- [CA21060]
- [CA77658]
- [CA11789]
- [CA60138]
- [CA41287]
- [CA16450]
- [CA77440]
Ask authors/readers for more resources
Introduction: The Cancer and Leukemia Group B (CALGB)conducted a multi-center phase II trial to evaluate the efficacy and safety of vatalanib in previously untreated patients with malignant mesothelioma and to evaluate potential biomarkers of disease response (CALGB 30107). Methods: Treatment consisted of vatalanib 1250 mg given orally once daily. CT scans were obtained at baseline and every 6 weeks thereafter. Baseline serum levels of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), thrombospondin-1 (TSP-1), and mesothelin were obtained. The primary endpoint was 3-month progression-free survival (PFS). Results: Forty-seven patients enrolled at 19 centers. The median age was 75 years, and the majority of patients (79%) had an ECOG performance status of 1. Tumors were classified as epithelial (77%), sarcomatoid (10%), or mixed (9%) histology. Toxicity was mild; the most common grade 3/4 adverse events were neutropenia (2%), nausea (15%), elevated alanine aminotransferase (11%), hypertension (2%), and gastrointestinal bleeding (2%). Partial responses were observed in 6% of patients and stable disease in 72% of patients. The 3-month PFS rate was 55% (95% CI: 40%, 68%). The median PFS was 4.1 months. Median overall survival was 10.0 months. There was no correlation between serum levels of VEGF, PDGF, TSP-1, or mesothelin and treatment response, PFS, or survival. Conclusions: Vatalanib as a single agent with this dose and schedule does not warrant further study in this disease. (c) 2011 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available